| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Amphastar Pharmaceuticals, Inc.$18.72
-0.3 (-1.58%)
B 62Pipeline Score Undervalued Generics · Clinical
Market Cap
813.51 M
EPS
1.71
P/E Ratio
11.08 $
Value Trade
9.20 M
SEC Financials
Q1 2026Dilution Risk
Revenue
171.17 M
R&D Expenses
26.74 M
Operating CF
47.84 M
Total Assets
1.65 B
Total Liabilities
874.77 M
Equity
773.39 M
D/E Ratio
12,345
6.6 %
Week
-13.97 %
1 Month
-35.58 %
3 Month
-27.66 %
6 Month
-7.11 %
5 Year
163 %
All Time
Cash Data
Cash Position
291.95 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
311.05 K
52 Week Range
16.65 - 31.26
% held by Insiders
26 %
% held by Institutions
74.82 %
Enterprise Value
1.21 B
Total Shares
44.08 M
Short %
12.74 %
Float Shares
30.19 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amphastar Pharmaceuticals, Inc.
216Total events
2Upcoming
69Tier-1 (high impact)
2014 – 2026Coverage
Upcoming catalysts 2
Event history 214
Jun 3, 2026
May 7, 2026
●NDA SubmissionRegulatory Filing
One ANDA and one biosimilar insulin candidate filed with FDA
Q2 2026
▲Product LaunchPost-Market
Planned commercial launch of Ipratropium Bromide HFA Inhalation Aerosol
maintenance treatment of bronchospasm associated with COPDsource ↗
Feb 24, 2026
▲FDA ApprovalFDA Decision
FDA approval of Ipratropium Bromide HFA Inhalation Aerosol ANDA
maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysemasource ↗
Feb 24, 2026
▲Exclusivity GrantedIP / Competition
180-day generic drug exclusivity granted for Ipratropium Bromide HFA
maintenance treatment of bronchospasm associated with COPDsource ↗
Jan 12, 2026
▲Partnership / LicenseAMP-110Corporate
Exclusive license agreement with Nanjing Hanxin for AMP-110
inflammatory and autoimmune conditionssource ↗
Q1 2026
▲Partnership / LicenseCorporate
Exclusive license agreement for fully synthetic corticotropin compound with Nanjing Hanxin Pharmaceutical Technology Co., Ltd.
Nov 6, 2025
▲FDA Approvaliron sucrose injectionApprovedFDA Decision
FDA approval of iron sucrose injection
iron deficiencysource ↗
Nov 6, 2025
▲Product Launchiron sucrose injectionApprovedPost-Market
Launch of iron sucrose injection
iron deficiencysource ↗
Drug Pipeline Intelligence
B62
Pipeline Score $7.8B
Pipeline ValueUndervalued
Valuation Signal9
Drugs Scored9.6x
rNPV / MCap Top 90%
Micro Cap (rank 92 of 911)
Percentile RankAmphastar Pharmaceuticals, Inc. holds a solid B-grade pipeline (62/100), with $19.4B risk-adjusted pipeline value, led by epinephrine in Asthma (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| epinephrine Small molecule | Asthma | Phase 3 | NCT01143051 | 58% | $4.4B | COMPLETED | 420 | - | - | Jun 1, 2010 | - | Sep 25, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AMPH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AMPH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AMPHAmphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Amphastar Pharmaceuticals is facing an investigation by Johnson Fistel regarding potential violations of federal securities laws, particularly after the company reported a significant decline in BAQSIMI revenues. Despite an increase in the units sold, the overall revenue dropped due to lower average selling prices influenced by higher rebates and 340B pharmacy discounts. Following the financial disclosures, the company's stock price saw a drastic fall of more than 20%, prompting concerns among investors. The investigation seeks to address whether these losses can be recovered under federal securities laws.
Read more →AMPHAmphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference
Amphastar Pharmaceuticals announced that CFO Bill Peters and EVP Jacob Liawatidewi will present at the 2026 Jefferies Healthcare Conference on June 3, 2026. The presentation will be available via webcast for 30 days post-event. This engagement underscores Amphastar's commitment to investor relations and transparency.
Read more →AMPH▼ -20.9%on this news
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Amphastar Pharmaceuticals reported financial results for Q1 2026, achieving net revenues of $171.2 million and a GAAP net income of $6.4 million. The company highlighted the successful launch of Ipratropium Bromide HFA and advancements in its product pipeline. However, it faced challenges with decreased sales in certain products due to pricing and competition.
Read more →AMPH▼ -5.3%on this news· ran to -29% by day 3
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended
Amphastar Pharmaceuticals reported its financial results for the year ended December 31, 2025, highlighting a strategic focus on commercial strength and scientific innovation. The company experienced sustained growth from its product BAQSIMI and received FDA approvals for new complex generics. However, both net revenues and GAAP net income saw decreases compared to the prior year, with particular declines noted in glucagon sales. The company is also advancing multiple proprietary product candidates targeting significant market opportunities.
Read more →AMPHAmphastar Announces FDA Approval for Ipratropium Bromide HFA
Amphastar Pharmaceuticals has received FDA approval for its Ipratropium Bromide HFA Inhalation Aerosol, confirming it as bioequivalent to Boehringer Ingelheim's Atrovent®HFA. The product is eligible for 180 days of generic exclusivity, starting upon launch. Amphastar plans to introduce this inhalation aerosol in early Q2 2026, aiming to enhance its respiratory product offerings.
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026
Amphastar Pharmaceuticals, Inc. will announce its fourth quarter earnings for 2025 on February 26, 2026, after market close. A conference call is scheduled for 2:00 p.m. Pacific Time to discuss the financial results. The call will be accessible via phone and webcast, with a replay available shortly after.
Read more →AMPH▲ +6%on this news
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound Agreement expands Amphastar's proprietary peptide pipelin
Amphastar Pharmaceuticals has entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical for the development of AMP-110, a fully synthetic ACTH analog targeting inflammatory and autoimmune conditions. This new addition is seen as crucial for expanding Amphastar's peptide portfolio. The agreement includes an upfront payment, milestone payments, and royalty arrangements which could yield significant revenue. AMP-110 is currently undergoing early-phase clinical trials, suggesting a promising safety profile compared to traditional products.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended
Amphastar Pharmaceuticals announced its financial results for the quarter ending September 30, 2025, highlighting a 14% revenue growth for its product BAQSIMI. The company received FDA approval for iron sucrose injection, expanding its offerings and enhancing patient access. Despite this, GAAP net income saw a significant decline, and overall product revenues experienced mixed results, with notable drops in some key product sales. Additionally, the company entered into a licensing agreement for three novel peptides aimed at high-growth markets, positioning itself for future growth.
Read more →AMPH▲ +10.9%on this news
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Agreement strengthens proprietary peptide pipeline targeting high-value oncology and
Amphastar Pharmaceuticals has entered into an exclusive licensing agreement with Nanjing Anji Biotechnology Co., Ltd. to develop and commercialize three novel peptide products in the U.S. and Canada. These include a peptide aimed at cancer suppression, a docetaxel conjugate designed to improve selectivity and safety, and a topical eye drop for wet age-related macular degeneration. The agreement outlines substantial financial commitments and milestone payments, further bolstering Amphastar's focus on innovative pharmaceutical developments to address pressing medical needs.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 20 24 Reports Net Revenues of $186.5 Million for the Three Months Ended
Amphastar Pharmaceuticals reported its financial results for the fourth quarter and full year ending December 31, 2024. The company achieved net revenues of $186.5 million for the fourth quarter, a 5% increase, and surpassed its long-term goal for Primatene MIST sales with over $100 million achieved in 2024. However, they saw declines in revenues for certain products like Glucagon and Epinephrine, and an increase in cost of revenues was reported. Future growth is anticipated from a robust pipeline, including biosimilars and generic drugs targeting high market sizes.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 24 Reports Net Revenues of $191.2 Million for the Three Months Ended
Amphastar Pharmaceuticals reported financial results for the third quarter of 2024, highlighting net revenues of $191.2 million, a 6% increase from the previous year. Growth was notably driven by sales of BAQSIMI and Primatene MIST, with the company aiming for sustainable expansion through proprietary products and biosimilars. However, there were challenges, including a decrease in GAAP net income and impact from Hurricane Helene causing shipment delays. The company has also authorized a $50 million increase to its share buyback program to enhance shareholder value.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 24 Reports Net Revenues of $182.4 Million for the Three Months Ended
Amphastar Pharmaceuticals has announced its financial results for the second quarter of 2024, showcasing notable growth with net revenues of $182.4 million, up 25% year-over-year. The success of BAQSIMI is highlighted as a key factor in sales growth, alongside a rise in net income to $37.9 million. However, the company faced challenges with certain products experiencing significant revenue declines. Additionally, costs of revenue increased, affecting overall profit margins.
Read more →AMPHAmphastar Announces Additional $50 Million Increase to its Share Buyback Program
Amphastar Pharmaceuticals has announced a $50 million increase to its share buyback program approved by the Board of Directors. This initiative aims to counteract the dilution caused by the company's equity compensation strategies. The share repurchases may occur through various means, depending on market conditions and regulatory compliance. Amphastar also reported ongoing development efforts for several drugs, targeting significant market sizes across multiple product categories.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 23 Reports Net Revenues of $178.1 Million for the Three Months Ended
Amphastar Pharmaceuticals announced strong financial results for the quarter and year ending December 31, 2023, reporting net revenues of $178.1 million for Q4 2023, an increase of 32% year-over-year. The company's success was driven by notable sales growth in glucagon and the acquisition of BAQSIMI, enhancing its diabetes management offerings. The announcement highlighted a successful submission of a Biologics License Application for Insulin Aspart (AMP-004), indicating ongoing pipeline development. Overall, Amphastar enters 2024 with positive momentum and a robust financial performance.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 23 Reports Net Revenues of $180.6 Million for the Three Months Ended
Amphastar Pharmaceuticals reported strong financial results for the third quarter of 2023, with net revenues reaching $180.6 million and a significant increase in GAAP net income to $49.2 million. The company's performance was bolstered by the success of its diabetes portfolio, notably from the acquisition of BAQSIMI. Despite the positives, there were declines in certain product revenues, which could indicate risks in specific areas of their product lineup. Overall, the company maintains a robust pipeline aimed at future growth.
Read more →AMPHAmphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Amphastar Pharmaceuticals has announced its intention to privately offer $300 million in convertible senior notes due 2029, with an option for an additional $45 million. The proceeds will primarily be used for repaying existing borrowings and potential common stock repurchases. The notes, which will be offered to qualified institutional buyers, will not be registered under the Securities Act. Amphastar has not predetermined specific uses for all net proceeds, and the success of the offering is contingent on market conditions.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 23 Reports Net Revenues of $145.7 Million for the Three Months Ended
Amphastar Pharmaceuticals reported robust financial results for the second quarter of 2023, with net revenues reaching $145.7 million, marking an 18% increase year-over-year. Significant contributions to revenue came from glucagon and phytonadione, alongside new product sales, bolstering the company's financial position. However, there were notable declines in revenue for some established products, indicating areas of concern. The completion of the BAQSIMI acquisition also enhances the company's product portfolio and strategic direction.
Read more →AMPHAmphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Amphastar Pharmaceuticals has finalized the acquisition of BAQSIMI from Eli Lilly for $500 million, with an additional $125 million due next year and up to $450 million in contingent payments based on milestone achievements. This acquisition aims to enhance Amphastar's diabetes product offerings and solidify its market presence. BAQSIMI, indicated for severe hypoglycemia in diabetes patients aged 4 and older, comes with specific safety warnings, underscoring the need for careful usage and medical guidance.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 202 3 Reports Net Revenues of $140.0 Million for the Three Months Ended
Amphastar Pharmaceuticals reported its financial results for the first quarter ended March 31, 2023, highlighting net revenues of $140 million, a 16% increase compared to the same period last year. The increase in revenue is attributed to strong sales of key products such as glucagon, Primatene MIST, and epinephrine. The company expressed optimism about future growth, particularly with the potential acquisition of BAQSIMI, which aims to strengthen its diabetes product offerings. Overall, the financial performance reflects a positive trend, bolstered by strategic product enhancements and market expansion.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 22 Reports Net Revenues of $135.0 Million for the Three Months Ended
Amphastar Pharmaceuticals reported robust financial results for the fourth quarter and the full year ending December 31, 2022, with net revenues reaching $135.0 million, marking a 12% increase year-over-year. The company's GAAP net income grew to $33.9 million in Q4 2022, a significant rise from $19.8 million in the same quarter of the previous year. With plans to launch several new products in 2023 and ongoing development of additional generic and proprietary products, Amphastar is well-positioned for future growth.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 22 Reports Net Revenues of $120.1 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022 Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 RANCHO CUCAMONGA, CA - November 7, 2022 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amph
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 22 Reports Net Revenues of $123.5 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022 Reports Net Revenues of $123.5 Million for the Three Months Ended June 30, 2022 RANCHO CUCAMONGA, CA - August 8, 2022 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or th
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 202 2 Reports Net Revenues of $120.4 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022 Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA - May 9, 2022 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 21 Reports Net Revenues of $120.9 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021 Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA - March 10, 2022 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AM
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 21 Reports Net Revenues of $112.2 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2021 Reports Net Revenues of $112.2 Million for the Three Months Ended September 30, 2021 RANCHO CUCAMONGA, CA - November 8, 2021 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amph
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 21 Reports Net Revenues of $101.7 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021 Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021 RANCHO CUCAMONGA, CA - August 9, 2021 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or th
Read more →AMPHAmphastar Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference
Amphastar Pharmaceuticals announced its participation in the Human Health Innovation Conference, scheduled for June 22, 2021. Key executives, including the CFO and VPs, will present at the event. The presentation will be available via webcast for 90 days, allowing broader access to their insights and updates.
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
Amphastar Pharmaceuticals will present at the Jefferies Virtual Healthcare Conference on June 3, 2021. Key executives, including the CFO and V.P. of Corporate Communications, will participate in an analyst-moderated fireside chat. The presentation will be available via webcast for 90 days, enhancing accessibility for stakeholders.
Read more →AMPHAmphastar Announces Buyback of 26% of the Equity in its ANP Subsidiary and Spin-off its Hanxin Subsidiary
Amphastar Pharmaceuticals announced a restructuring of its Chinese subsidiaries, including a buyback of 26% equity in Amphastar Nanjing Pharmaceuticals and the spin-off of Nanjing Hanxin Pharmaceutical Technology. The restructuring, which requires regulatory approval, aims to strengthen Amphastar's API manufacturing capabilities and is expected to positively impact earnings per share in the coming years.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2021
Amphastar Pharmaceuticals reported net revenues of $103.0 million for Q1 2021, marking a strong sales growth period. The company highlighted the successful launch of glucagon and increased sales of Primatene Mist® and epinephrine products. With a robust pipeline, Amphastar anticipates continued growth throughout the year.
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Morphine Sulfate Injection
Amphastar Pharmaceuticals has received FDA approval for its Morphine Sulfate injection, which is intended for managing severe pain through Patient-Controlled Analgesia. This approval allows the company to market the product officially, transitioning from its previous grandfather status. The company also has a robust pipeline, including several ANDAs and biosimilars, indicating strong future growth potential.
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 6th, 2021
Amphastar Pharmaceuticals will announce its first quarter 2021 earnings on May 6, 2021, after market close. The company will hold a conference call at 2:00 p.m. PT to discuss the results. Amphastar specializes in developing and marketing complex injectable and inhalation products, primarily for clinical settings.
Read more →AMPHAmphastar Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference
Amphastar Pharmaceuticals will participate in the 20th Annual Needham Virtual Healthcare Conference, featuring key executives in a fireside chat. The event is scheduled for April 13, 2021, and will be accessible via webcast for 90 days. This engagement underscores Amphastar's focus on communication with investors and stakeholders.
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Dextrose Injection
Amphastar Pharmaceuticals has received FDA approval for its Dextrose injection 50% in a prefilled syringe system. This product, previously marketed under a grandfather clause, is expected to alleviate shortages in the market. The approval underscores Amphastar's manufacturing capabilities and opens avenues for enhanced revenue from this essential product.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 20 20 Reports Net Revenues of $95.9 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2020 Reports Net Revenues of $95.9 Million for the Three Months Ended December 31, 2020 RANCHO CUCAMONGA, CA - March 15, 2021 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMP
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 15th, 2021
RANCHO CUCAMONGA, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2020 ended December 31, 2020, after the market closes on Monday, March 15th, 2021, and will hold a
Read more →AMPHAmphastar Pharmaceuticals to Present at the Raymond James 2021 Institutional Healthcare Conference
RANCHO CUCAMONGA, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, V.P of Corporate Communications and HR, Tony Marrs, Sr. V.P Regulatory Affairs and Clinical Operations, and Jacob Liawat
Read more →AMPHForward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management's current expectations and assumptions and on information currently
Available OTC nationwide at: 19 Primatene MIST : Sales Trend 20 Near-Term Growth Points in 2021 Glucagon Injection Kit launch planned February 2021 Primatene MIST indicated for intermittent asthma - Adult asthma patients: 19.2 million per CDC* - Intermittent adult asthma patients
Read more →AMPHAmphastar Announces Approval for Glucagon for Injection Kit, 1mg
RANCHO CUCAMONGA, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Gluc
Read more →AMPHAMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN 1. Purposes of the Plan . The purposes of this Plan are: to attract and retain the best available personnel for positions of substantial responsibility, to provi
AMPHASTAR PHARMACEUTICALS, INC. 2015 EQUITY INCENTIVE PLAN 1.Purposes of the Plan. The purposes of this Plan are: to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees, Directors and Consul
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 20 Reports Net Revenues of $83.4 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020 Reports Net Revenues of $83.4 Million for the Three Months Ended September 30, 2020 RANCHO CUCAMONGA, CA - November 6, 2020 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Ampha
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2020
RANCHO CUCAMONGA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2020 ended September 30, 2020, before the market opens on Friday, November 6th, 2020, and will hold
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection
RANCHO CUCAMONGA, Calif., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) approved the Company’s Abbreviated New Drug Application (“ANDA”) for Atropine Sulfate injection 0.1mg/mL in the
Read more →AMPHAmphastar Pharmaceuticals to Present at the Wells Fargo 2020 Virtual Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs a
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 20 20 Reports Net Revenues of $85.8 Million for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2020 Reports Net Revenues of $85.8 Million for the Three Months Ended June 30, 2020 RANCHO CUCAMONGA, CA - August 6, 2020 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6th, 2020
RANCHO CUCAMONGA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2020 ended June 30, 2020, after the market closes on Thursday, August 6th, 2020, and will hold a co
Read more →AMPHAmphastar Pharmaceuticals to Present at the BMO Prescriptions for Success Healthcare Conference
RANCHO CUCAMONGA, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs an
Read more →AMPHAmphastar Pharmaceuticals to Present at the Raymond James Virtual 2020 Human Healthcare Innovation Conference
RANCHO CUCAMONGA, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, Dan Dischner, Vice President of Corporate Communications and Human Resources, and Tony Marrs, Sr. Vice President Regulatory Affairs an
Read more →AMPHAmphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) Multiple-Dose Vial
RANCHO CUCAMONGA, Calif., June 09, 2020 (GLOBE NEWSWIRE) -- Amphastar® Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Succinylcholine Chloride I
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2020
RANCHO CUCAMONGA, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2020 ended March 31, 2020, after the market closes on Thursday, May 7th, 2020, and will hold a confer
Read more →AMPHAmphastar Pharmaceuticals, Inc. Receives FDA Approval for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
RANCHO CUCAMONGA, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) (“Amphastar”), today announces that the U.S. Food and Drug Administration (“FDA”) has granted approval of its Abbreviated New Drug Application (“ANDA”) for Epinephrine In
Read more →AMPHAmphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure RANCHO CUCAMONGA, CA –
Amphastar Pharmaceuticals, Inc. Announces Simplification of Management Structure RANCHO CUCAMONGA, CA April 13, 2020 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ( Amphastar or the Company ), a California-based, specialty, generic pharmaceutical company, today announces a rece
Read more →AMPHAmphastar Pharmaceuticals to Present at the 19th Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, April 09, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 12:5
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12th, 2020
RANCHO CUCAMONGA, Calif., March 05, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2019 ended December 31, 2019, after the market closes on Thursday, March 12th, 2019, and will hold
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Supplement to its Abbreviated New Drug Application for Sodium Bicarbonate Injection, USP 8.4%, 50mEq/50mL
RANCHO CUCAMONGA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) granted approval of its supplemental Abbreviated New Drug Application for Sodium Bicarbonate Injection, US
Read more →AMPHAmphastar Announces the Receipt of a MINOR CRL for Epinephrine Injection, USP 30mg/30mL (1mg/mL) Multiple Dose Vial
RANCHO CUCAMONGA, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that on January 24, 2020, the U.S. Food and Drug Administration (“FDA”) issued a “MINOR” Complete Response Letter (“CRL”) for its Abbreviated New Drug Application
Read more →AMPHAmphastar Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 31st Annual Piper Jaffray Healthcare Conference on Wednesday, December 4, 2019
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 3:20 p.m. GMT in Aldwych, L
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7th, 2019
RANCHO CUCAMONGA, Calif., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its third quarter of 2019 ended September 30th, 2019, after the market closes on Thursday, November 7th, 2019, and will h
Read more →AMPHAmphastar Pharmaceuticals to Present at the Wells Fargo 2019 Healthcare Conference
RANCHO CUCAMONGA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Wells Fargo 2019 Healthcare Conference on Thursday, September 5, 2019 at 3:05
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2019
RANCHO CUCAMONGA, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2019 ended June 30, 2019, after the market closes on Wednesday, August 7, 2019, and will hold a con
Read more →AMPHAmphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz RANCHO CUCAMONGA, CA –
Amphastar Pharmaceuticals, Inc. Announces Settlement in Litigation with Momenta and Sandoz
Read more →AMPHAmphastar Pharmaceuticals to Present at the Raymond James Life Sciences and MedTech Healthcare Conference
RANCHO CUCAMONGA, Calif., June 14, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, will be presenting at the Raymond James Life Sciences and MedTech Healthcare Conference on Wednesday, June 19, 2019 at 4:10 p.m. Easte
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
RANCHO CUCAMONGA, Calif., May 31, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Jefferies 2019 Healthcare Conference on Wednesday, June 5, 2019 at 8:30 a.m. Ea
Read more →AMPHAmphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference 2019
RANCHO CUCAMONGA, Calif., May 10, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2019
RANCHO CUCAMONGA, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its first quarter of 2019 ended March 31, 2019, after the market closes on Thursday, May 9, 2019, and will hold a conferen
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Enoxaparin Sodium Injection 300mg/3mL (100mg/mL) Multiple Dose Vial
RANCHO CUCAMONGA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (FDA) granted approval of its Abbreviated New Drug Application (“ANDA”) for Enoxaparin Sodium Injection 300mg/3mL (100
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2019
RANCHO CUCAMONGA, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2018 ended December 31, 2018, after the market closes on Tuesday, March 12, 2019, and will hold a
Read more →AMPHAmphastar Pharmaceuticals, Inc. Announces Launch of Primatene MIST to Nationwide Retail Pharmacies
RANCHO CUCAMONGA, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that Primatene® MIST has been launched. Primatene® MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA-approved meter
Read more →AMPHAmphastar Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference 2018
RANCHO CUCAMONGA, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO will be presenting at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 p.m. Eastern Time, Ne
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
RANCHO CUCAMONGA, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 2:00
Read more →AMPHAmphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene ® MIST Primatene ® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler RANCHO CUCAMONGA, CA –
Amphastar Pharmaceuticals, Inc. Announces Reintroduction of Primatene MIST Amphastar is a specialty pharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation and intra-nasal pro
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2018
RANCHO CUCAMONGA, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018, after the market closes on Thursday, November 8, 2018, and will hold
Read more →AMPHAmphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference 2018
RANCHO CUCAMONGA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 9:10 a.m.
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2018
RANCHO CUCAMONGA, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its second quarter of 2018 ended June 30, 2018, after the market closes on Wednesday, August 8, 2018, and will hold a con
Read more →AMPHAmphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc. RANCHO CUCAMONGA, CA –
Amphastar Announces Expansion of Amphastar Nanjing Pharmaceuticals Inc. RANCHO CUCAMONGA, CA July 9, 2018 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals Inc. ( ANP ). To date, ANP has provid
Read more →AMPHAmphastar Announces Approval for Isoproterenol Hydrochloride Injection, USP
RANCHO CUCAMONGA, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has granted approval of its abbreviated new drug application (“ANDA”) for Isoproterenol Hydrochloride Injection,
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference 2018
RANCHO CUCAMONGA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, will be presenting at the Jefferies Healthcare Conference on Tuesday, June 5, 2018 at 3:00 p.m. Eastern Time in New York, NY. This pre
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Semi-Purified Heparin at Amphastar Nanjing Pharmaceuticals
RANCHO CUCAMONGA, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) supplement for the manufacture of sem
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection
RANCHO CUCAMONGA, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Calcium Chloride injection 10% in
Read more →AMPHAmphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2018
RANCHO CUCAMONGA, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO, will be presenting at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018 a
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2018
RANCHO CUCAMONGA, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2018 ended March 31, 2018, after the market closes on Wednesday, May 9, 2018, and will hold a conferen
Read more →AMPHAmphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference
RANCHO CUCAMONGA, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO will be presenting at the Needham‘s 17th Annual Healthcare Conference on Wednesday, March 28, 2018 at 9:30 a.m. Eastern Time in New Yor
Read more →AMPHAmphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. RANCHO CUCAMONGA, CA –
Amphastar Announces Final Judgment in the Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. RANCHO CUCAMONGA, CA March 21, 2018 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that on March 20, 2018, the United States Court for the District of Mass
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017 Reports Net Revenues of $60.4 Million for the Three Months Ended December 31, 2017 RANCHO CUCAMONGA, CA March 12, 2018 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 12, 2018
RANCHO CUCAMONGA, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2017 ended December 31, 2017, after the market closes on Monday, March 12, 2018, and will hold a co
Read more →AMPHAmphastar Announces Approval for Sodium Nitroprusside Injection, USP
RANCHO CUCAMONGA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of its abbreviated new drug application (“ANDA”) for Sodium Nitroprusside Injection 25mg
Read more →AMPHAmphastar Announces Approval for Medroxyprogesterone Acetate Injectable Suspension, USP
RANCHO CUCAMONGA, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that today the U.S. Food and Drug Administration (“FDA”) granted approval of two abbreviated new drug applications (ANDAs) for Medroxyprogesterone Acetate Injectab
Read more →AMPHAmphastar Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2017
RANCHO CUCAMONGA, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2017, ended September 30, 2017, after the market closes on Wednesday, November 8, 2017, and will hold
Read more →AMPHAmphastar Announces Approval for Neostigmine Methylsulfate Injection, USP
RANCHO CUCAMONGA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration (“FDA”) granted approval of its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate Injection, USP, 1
Read more →AMPHAmphastar Pharmaceuticals Receives FDA Approval for Sodium Bicarbonate Injection
RANCHO CUCAMONGA, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that on September 19, 2017, the U.S. Food and Drug Administration (“FDA”) granted approval of the company’s abbreviated new drug application (“ANDA”) for Sodium Bi
Read more →AMPHAmphastar Pharmaceuticals to Present at the 2017 Wells Fargo Securities Healthcare Conference
RANCHO CUCAMONGA, Calif., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2017 Wells Fargo Securities Healthcare Conference on Wednesday, September 6, 2017 at 1:50 p.m. Easter
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 9, 2017
RANCHO CUCAMONGA, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2017, ended June 30, 2017, after the market closes on Wednesday, August 9, 2017, and will hold a con
Read more →AMPHAmphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. RANCHO CUCAMONGA, CA –
Amphastar Announces Jury Verdict in Patent Litigation against Momenta Pharmaceuticals, Inc. and Sandoz Inc. RANCHO CUCAMONGA, CA July 24, 2017 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that a federal jury delivered a unanimous verdict in favor of Amphastar i
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
RANCHO CUCAMONGA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President, will be presenting at the Jefferies Global Healthcare Conference on Tuesday, June 6, 2017 at 10:00 a.m. Eastern Time in New Yo
Read more →AMPHAmphastar Pharmaceuticals to Present at the 20th Annual Bank of America Merrill Lynch Health Care Conference
RANCHO CUCAMONGA, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 20th Annual Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 at 5:00 p.m.
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on May 8, 2017
RANCHO CUCAMONGA, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2017 ended March 31, 2017, after the market closes on Monday, May 8th, 2017, and will hold a conferenc
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2017
RANCHO CUCAMONGA, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2017 ended March 31, 2017, after the market closes on Monday, May 8th, 2017, and will hold a conferenc
Read more →AMPHAmphastar Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 16th Annual Needham Healthcare Conference on Wednesday, April 5, 2017 at 12:50 p.m. Eastern Time in
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 13, 2017
RANCHO CUCAMONGA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2016 ended December 31, 2016, after the market closes on Monday, March 13th, 2017, and will hold a
Read more →AMPHAmphastar Announces the Receipt of a CRL for Intranasal Naloxone for the Emergency Treatment of Opioid Overdose
RANCHO CUCAMONGA, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced today that the U.S. Food and Drug Administration (“FDA”) issued a Complete Response Letter (“CRL”) for its New Drug Application (“NDA”) for Naloxone Hydrochloride
Read more →AMPHAmphastar Pharmaceuticals Receives Complete Response Letter for Primatene ® Mist RANCHO CUCAMONGA, CA –
Amphastar Pharmaceuticals Receives Complete Response Letter for Primatene Mist RANCHO CUCAMONGA, CA December 27, 2016 Amphastar Pharmaceuticals, Inc., (NASDAQ: AMPH) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its w
Read more →AMPHAmphastar Pharmaceuticals to Present at the 2016 Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2016 Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 11:00 a.m. Eastern Time i
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2016
RANCHO CUCAMONGA, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2016 ended September 30, 2016, after the market closes on Tuesday, November 8, 2016, and will hold a
Read more →AMPHAmphastar Pharmaceuticals to Present at the 2016 Wells Fargo Healthcare Conference
RANCHO CUCAMONGA, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2016 Wells Fargo Healthcare Conference on Thursday, September 08, 2016 at 2:20 p.m. Eastern Time in
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30 , 201 6 Reports Net Revenues of $ 68.0 M illion for the Three Months Ended
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2016 Reports Net Revenues of $68.0 Million for the Three Months Ended June 30, 2016 RANCHO CUCAMONGA, CA August 8, 2016 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ( Amphastar or the Comp
Read more →AMPHAmphastar Pharmaceuticals, Inc. Purchases International Medication Systems (UK) Limited from UCB PHARMA GmbH RANCHO CUCAMONGA, CA –
Amphastar Pharmaceuticals, Inc. Purchases International Medication Systems (UK) Limited from UCB PHARMA GmbH RANCHO CUCAMONGA, CA August 4, 2016 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ( Amphastar or the Company ), announced today that, through its wholly owned UK subsidi
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2016
RANCHO CUCAMONGA, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2016 ended June 30, 2016, after the market closes on Monday, August 8, 2016, and will hold a confere
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
RANCHO CUCAMONGA, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, 2016 at 2 p.m. Eastern Time in New York, NY.
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the F irst Quarter Ended M arch 31, 2016 Reports Net Revenues of $ 59.4 M illion for the F irst Quarter Ended
Amphastar Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2016 Reports Net Revenues of $59.4 Million for the First Quarter Ended March 31, 2016 RANCHO CUCAMONGA, CA May 9, 2016 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ( Amphastar or the Com
Read more →AMPHAmphastar Pharmaceuticals to Present at the 2016 Bank of America Merrill Lynch 19th Annual Health Care Conference
RANCHO CUCAMONGA, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the Bank of America Merrill Lynch 19th Annual Health Care Conference on Thursday, May 12, 2016 at 9:20 a.m
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2016
RANCHO CUCAMONGA, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2016 ended March 31, 2016, after the market closes on Monday, May 9, 2016, and will hold a conference
Read more →AMPHAmphastar Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 12:50 p.m. Eastern Dayligh
Read more →AMPHAmphastar Pharmaceuticals Reports Financial Results for the Fourth Quarter and Fiscal Year Ended
Amphastar Pharmaceuticals Reports Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2015 Reports Net Revenues of $76.9 Million for the Fourth Quarter Ended December 31, 2015 RANCHO CUCAMONGA, CA March 14, 2016 Amphastar Pharmaceuticals, Inc. (NASDAQ: A
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 14, 2016
RANCHO CUCAMONGA, Calif., March 11, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2015 ended December 31, 2015, after the market closes on Monday, March 14, 2016, and will hold a co
Read more →AMPHAmphastar Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference
RANCHO CUCAMONGA, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Jason Shandell, President and Bill Peters, CFO will be presenting at the 27th Annual Piper Jaffray Healthcare Conference o
Read more →AMPHAmphastar Pharmaceuticals Reports Net Revenues of $ 63.9 M illion for the T hird Quarter Ended September 30 , 2015 . RANCHO CUCAMONGA, CA – November 12 , 2015 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH
Amphastar Pharmaceuticals Reports Net Revenues of $63.9 Million for the Third Quarter Ended September 30, 2015. RANCHO CUCAMONGA, CA November 12, 2015 Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ( Amphastar or the Company ) today reported results for the third quarter ended S
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 12, 2015
RANCHO CUCAMONGA, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2015 ended September 30, 2015, after the market closes on Thursday, November 12, 2015, and will hold a
Read more →AMPHAmphastar Pharmaceuticals Launches Amphadase(R)
RANCHO CUCAMONGA, Calif., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that it began shipping Amphadase (hyaluronidase injection). This launch marks the first product made using starting material fr
Read more →AMPHAmphastar Pharmaceuticals Reports Net Revenues of $53.9 Million for the Second Quarter Ended June 30, 2015
RANCHO CUCAMONGA, Calif., Aug. 12, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the second quarter ended June 30, 2015. Net revenues of $53.9 million for the second quarter GAAP net loss of $6.6
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 12, 2015
RANCHO CUCAMONGA, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2015 ended June 30, 2015, after the market closes on Wednesday, August 12, 2015, and will hold a conf
Read more →AMPHAmphastar Pharmaceuticals Receives Approval for AMPHADASE(R) Supplement, Marking the First Product From Its China Facility
RANCHO CUCAMONGA, Calif., June 22, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") announced today that the U.S. Food and Drug Administration ("FDA") granted approval of the Company's New Drug Application ("NDA") supplement fo
Read more →AMPHAmphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference 2015
RANCHO CUCAMONGA, Calif., May 29, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced today that Jason Shandell, President will be presenting at the Jefferies Healthcare Conference on Wednesday, June 3, 2015 at 10:00 a.m. Eastern Time in New York, NY.
Read more →AMPHAmphastar Pharmaceuticals Reports Net Revenues of $56.9 Million for the First Quarter Ended March 31, 2015
RANCHO CUCAMONGA, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for the first quarter ended March 31, 2015. Net revenues of $56.9 million for the first quarter GAAP net loss of $0.7 m
Read more →AMPHAmphastar Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
RANCHO CUCAMONGA, Calif., May 11, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced today that Jason Shandell, President will be presenting at the Bank of America Merrill Lynch 2015 Health Care Conference on Thursday, May 14, 2015 at 9:20 a.m. Pacif
Read more →AMPHAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 13, 2015
RANCHO CUCAMONGA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced that the Company will release results for its first quarter of 2015 ended March 31, 2015, after the market closes on Wednesday, May 13, 2015, and will hold a conferen
Read more →AMPHAmphastar Pharmaceuticals to Present at the 14th Annual Needham Healthcare Conference
RANCHO CUCAMONGA, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced today that Jason Shandell, President will be presenting at the 14th Annual Needham Healthcare Conference on Wednesday, April 15, 2015 at 12:10 p.m. Eastern Standar
Read more →AMPHAmphastar Pharmaceuticals Reports Revenues of $55.9 Million for the Fourth Quarter Ended December 31, 2014
RANCHO CUCAMONGA, Calif., March 24, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for the fourth quarter ended December 31, 2014. Net revenues of $55.9 million for the fourth quarter GAAP net loss of
Read more →AMPHAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 24, 2015
RANCHO CUCAMONGA, Calif., March 17, 2015 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced that the Company will release results for its fourth quarter of 2014 ended December 31, 2014, after the market closes on Tuesday, March 24, 2015, and will hold a c
Read more →AMPHAmphastar Pharmaceuticals Reports Revenues of $59.7 Million for the Third Quarter Ended September 30, 2014
RANCHO CUCAMONGA, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for the third quarter ended September 30, 2014. Net revenues of $59.7 million for the third quarter GAAP net loss of $
Read more →AMPHAmphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 12, 2014
RANCHO CUCAMONGA, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced that the Company will release results for its third quarter of 2014 ended September 30, 2014, after the market closes on Wednesday, November 12, 2014, and will hold
Read more →AMPHAmphastar Pharmaceuticals Reports Revenues of $49.0 Million for the Second Quarter Ended June 30, 2014
RANCHO CUCAMONGA, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) ("Amphastar" or the "Company") today reported results for the second quarter ended June 30, 2014. Net revenues of $49.0 million for the second quarter GAAP net loss of $1.2
Read more →AMPHAmphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 12, 2014
RANCHO CUCAMONGA, Calif., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Nasdaq:AMPH) announced that the Company will release results for its second quarter of 2014 ended June 30, 2014, after the market closes on Tuesday, August 12, 2014, and will hold a confer
Read more →AMPHAmphastar Pharmaceuticals Announces Exercise of Over-Allotment Option
RANCHO CUCAMONGA, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Amphastar) (Nasdaq:AMPH), a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary in
Read more →AMPHAmphastar Pharmaceuticals Announces Pricing of Initial Public Offering
RANCHO CUCAMONGA, Calif., June 25, 2014 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (Amphastar) (Nasdaq:AMPH), a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary in
Read more →Competitive Position
How AMPH ranks across every disease it competes inCompetitive Position is a premium feature
See how AMPH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial